JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=2189539, encodeId=b53f218953953, content=偏重的研究方向：肿瘤;生信 经验分享：感觉非常非常不靠谱，一开始发邮件接受了，然后过了一会儿又发邮件说是发错了，给拒绝了。我是第一次这么遇到，太不靠谱了啊这期刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1868855082, createdName=ms8000002119425457, createdTime=Mon Feb 26 22:58:38 CST 2024, time=2024-02-26, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=2127011, encodeId=7336212e011e9, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：临床 经验分享：6号投稿，8号接收，19号在线发表，感谢编辑和审稿人，非常高效！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f2675544063, createdName=王子安那, createdTime=Wed Apr 19 12:29:46 CST 2023, time=2023-04-19, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2102655, encodeId=ad512102655db, content=偏重的研究方向：肿瘤 经验分享：11.16 submissions 11.17 Technical check in progress/ ready to be assigned to an editor 11.18 assigned editor 11.24 10 reviewers invited/ two reviewers accepted 11.25 1 Reviewer report received, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=84dc8360635, createdName=ms7000002055690251, createdTime=Fri Nov 25 22:06:27 CST 2022, time=2022-11-25, status=1, ipAttribution=东京都), GetPortalCommentsPageByObjectIdResponse(id=2151334, encodeId=ea63215133452, content=审稿速度:1.0 | 投稿命中率:95.0 经验分享：2023.07.13投稿 2023.07.23返修 2023.07.26上传返修稿 2023.08.04接受，整个过程20天，效率极高的杂志。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e5256534162, createdName=ms1000001224469901, createdTime=Fri Aug 04 22:14:11 CST 2023, time=2023-08-04, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2184341, encodeId=1c702184341fc, content=偏重的研究方向：肿瘤;基础 经验分享：有没有投过的前辈清楚，6个审稿人邀请16天了，也没人接受审稿，后续会怎么样，做的方向很大众化，感觉审稿人应该也不难找啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=15, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=52758133520, createdName=ms8000001112033195, createdTime=Sat Jan 27 22:14:24 CST 2024, time=2024-01-27, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2145621, encodeId=89262145621c2, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：肿瘤;生信 经验分享：肿瘤生信加了qPCR Submission status Date 29 Jun 2023 Submission accepted 29 Jun 2023 Submission under peer review 24 May 2023 Submission passed technical check 24 May 2023 Submission is under technical check 23 May 2023 Submission received 23 May 2023 一个月直接接收没有返修...现在还是懵的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=18, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=acc08219218, createdName=ms6000000533964556, createdTime=Fri Jun 30 09:58:44 CST 2023, time=2023-06-30, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2151188, encodeId=6f3b215118896, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤 经验分享：Part 1 审稿流程 Part 2 论坛常见问题审稿流程如下： 2023-06-20 投稿 2023-06-20 技术检查通过，安排审稿人 2023-06-23 第一个审稿人接受审稿 2023-06-25 第二个审稿人接受审稿 2023-07-01 第一个审稿意见已回 2023-07-07 第二个审稿意见已回 2023-07-09 编辑汇总意见建议小修 2023-07-13 提交返修 2023-07-25 接受后续包括编辑初步校对，选择OA还是非OA，最后校对都是在2、3天内完成，效率很高常见问题 1、文章参考格式：Endnote APA 6th（稍微参考一下既往杂志文章都不会问出这问题） 2、投稿状态的顺序：Under review（稿件进入投稿流程）→Reviewer Accepted（有审稿人开始审你的稿件了）→Reviews report received（编辑收到了审稿人的意见）→Reviewer reports received/ Ready for editor' s decision（所有的审稿人意见都回来之后，才会开始进入编辑审查阶段，等待编辑汇总意见之后会发给你对文章的处理决定） 3、回顾性研究，case report，基础，生信，meta都收录，被秒拒的大多是优先级不够或者没有任何亮点，纯生信不加试验没有亮点凭啥接收呢？杂志审稿人态度还是很端正的，结合审稿意见来看对文章的大方向和细节都是有要求的，没有给人不专业和水分较深的感觉 4、不建议文章在未发布前共享到Research Square平台上，在投稿时把那个选项X掉比较好 5、杂志可以共同通讯，在文章中标注清楚即可 6、在进入审稿流程后，所有的文章动态更新都只有通讯作者邮箱才能收到，第一作者如需及时了解动态建议勤登网站查看进程 7、OA和非OA在后续文章处理上没有任何区别，OA文章在增加引用量上有其固有优势，掏钱发文章这种事见仁见智，btw这个杂志APC偏贵, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=220, replyNumber=34, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f0b56493364, createdName=ms1000001633014790, createdTime=Thu Aug 03 23:00:50 CST 2023, time=2023-08-03, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2172859, encodeId=f3e821e285931, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：乳腺癌;蛋白家族 经验分享：Publishing and rights Submission status Date Publishing and rights complete 02 Sep 2023 Submission is in publishing and rights 28 Aug 2023 Peer review Submission status Date Submission accepted 17 Aug 2023 Submission under peer review 15 Aug 2023 Submission passed technical check 15 Aug 2023 Revision received 15 Aug 2023 Submission under peer review 13 Jul 2023 Technical check Submission status Date Submission passed technical check 13 Jul 2023 Amendment received 12 Jul 2023 Submission is under technical check 11 Jul 2023 Submission received Submission status Date Submission received 11 Jul 2023 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29e18780767, createdName=ms8000001760882210, createdTime=Mon Dec 04 13:56:12 CST 2023, time=2023-12-04, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2138638, encodeId=c55d213863802, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：外科;综述 经验分享：4.13投稿，5.23接收。一个月多一点直接接收。特别有效率。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221102/369591c85731477baa49cc9e4607aa59/710024ddb86e4cc79b2f2a73449bbb88.jpg, createdBy=041e5339211, createdName=胸外科小大夫, createdTime=Tue May 23 20:02:59 CST 2023, time=2023-05-23, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2130113, encodeId=f694213011372, content=五月三日投稿五月四日under review 一个审稿人已经接受了审稿不管中不中这本杂志在我心里都是神刊了处理效率太高了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d7528594085, createdName=ms6000001537745536, createdTime=Thu May 04 21:09:17 CST 2023, time=2023-05-04, status=1, ipAttribution=四川省)]

2024-02-26 ms8000002119425457 来自山西省

偏重的研究方向：肿瘤;生信
经验分享：感觉非常非常不靠谱，一开始发邮件接受了，然后过了一会儿又发邮件说是发错了，给拒绝了。我是第一次这么遇到，太不靠谱了啊这期刊

17 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2189539, encodeId=b53f218953953, content=偏重的研究方向：肿瘤;生信 经验分享：感觉非常非常不靠谱，一开始发邮件接受了，然后过了一会儿又发邮件说是发错了，给拒绝了。我是第一次这么遇到，太不靠谱了啊这期刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1868855082, createdName=ms8000002119425457, createdTime=Mon Feb 26 22:58:38 CST 2024, time=2024-02-26, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=2127011, encodeId=7336212e011e9, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：临床 经验分享：6号投稿，8号接收，19号在线发表，感谢编辑和审稿人，非常高效！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f2675544063, createdName=王子安那, createdTime=Wed Apr 19 12:29:46 CST 2023, time=2023-04-19, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2102655, encodeId=ad512102655db, content=偏重的研究方向：肿瘤 经验分享：11.16 submissions 11.17 Technical check in progress/ ready to be assigned to an editor 11.18 assigned editor 11.24 10 reviewers invited/ two reviewers accepted 11.25 1 Reviewer report received, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=84dc8360635, createdName=ms7000002055690251, createdTime=Fri Nov 25 22:06:27 CST 2022, time=2022-11-25, status=1, ipAttribution=东京都), GetPortalCommentsPageByObjectIdResponse(id=2151334, encodeId=ea63215133452, content=审稿速度:1.0 | 投稿命中率:95.0 经验分享：2023.07.13投稿 2023.07.23返修 2023.07.26上传返修稿 2023.08.04接受，整个过程20天，效率极高的杂志。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e5256534162, createdName=ms1000001224469901, createdTime=Fri Aug 04 22:14:11 CST 2023, time=2023-08-04, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2184341, encodeId=1c702184341fc, content=偏重的研究方向：肿瘤;基础 经验分享：有没有投过的前辈清楚，6个审稿人邀请16天了，也没人接受审稿，后续会怎么样，做的方向很大众化，感觉审稿人应该也不难找啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=15, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=52758133520, createdName=ms8000001112033195, createdTime=Sat Jan 27 22:14:24 CST 2024, time=2024-01-27, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2145621, encodeId=89262145621c2, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：肿瘤;生信 经验分享：肿瘤生信加了qPCR Submission status Date 29 Jun 2023 Submission accepted 29 Jun 2023 Submission under peer review 24 May 2023 Submission passed technical check 24 May 2023 Submission is under technical check 23 May 2023 Submission received 23 May 2023 一个月直接接收没有返修...现在还是懵的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=18, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=acc08219218, createdName=ms6000000533964556, createdTime=Fri Jun 30 09:58:44 CST 2023, time=2023-06-30, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2151188, encodeId=6f3b215118896, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤 经验分享：Part 1 审稿流程 Part 2 论坛常见问题审稿流程如下： 2023-06-20 投稿 2023-06-20 技术检查通过，安排审稿人 2023-06-23 第一个审稿人接受审稿 2023-06-25 第二个审稿人接受审稿 2023-07-01 第一个审稿意见已回 2023-07-07 第二个审稿意见已回 2023-07-09 编辑汇总意见建议小修 2023-07-13 提交返修 2023-07-25 接受后续包括编辑初步校对，选择OA还是非OA，最后校对都是在2、3天内完成，效率很高常见问题 1、文章参考格式：Endnote APA 6th（稍微参考一下既往杂志文章都不会问出这问题） 2、投稿状态的顺序：Under review（稿件进入投稿流程）→Reviewer Accepted（有审稿人开始审你的稿件了）→Reviews report received（编辑收到了审稿人的意见）→Reviewer reports received/ Ready for editor' s decision（所有的审稿人意见都回来之后，才会开始进入编辑审查阶段，等待编辑汇总意见之后会发给你对文章的处理决定） 3、回顾性研究，case report，基础，生信，meta都收录，被秒拒的大多是优先级不够或者没有任何亮点，纯生信不加试验没有亮点凭啥接收呢？杂志审稿人态度还是很端正的，结合审稿意见来看对文章的大方向和细节都是有要求的，没有给人不专业和水分较深的感觉 4、不建议文章在未发布前共享到Research Square平台上，在投稿时把那个选项X掉比较好 5、杂志可以共同通讯，在文章中标注清楚即可 6、在进入审稿流程后，所有的文章动态更新都只有通讯作者邮箱才能收到，第一作者如需及时了解动态建议勤登网站查看进程 7、OA和非OA在后续文章处理上没有任何区别，OA文章在增加引用量上有其固有优势，掏钱发文章这种事见仁见智，btw这个杂志APC偏贵, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=220, replyNumber=34, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f0b56493364, createdName=ms1000001633014790, createdTime=Thu Aug 03 23:00:50 CST 2023, time=2023-08-03, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2172859, encodeId=f3e821e285931, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：乳腺癌;蛋白家族 经验分享：Publishing and rights Submission status Date Publishing and rights complete 02 Sep 2023 Submission is in publishing and rights 28 Aug 2023 Peer review Submission status Date Submission accepted 17 Aug 2023 Submission under peer review 15 Aug 2023 Submission passed technical check 15 Aug 2023 Revision received 15 Aug 2023 Submission under peer review 13 Jul 2023 Technical check Submission status Date Submission passed technical check 13 Jul 2023 Amendment received 12 Jul 2023 Submission is under technical check 11 Jul 2023 Submission received Submission status Date Submission received 11 Jul 2023 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29e18780767, createdName=ms8000001760882210, createdTime=Mon Dec 04 13:56:12 CST 2023, time=2023-12-04, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2138638, encodeId=c55d213863802, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：外科;综述 经验分享：4.13投稿，5.23接收。一个月多一点直接接收。特别有效率。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221102/369591c85731477baa49cc9e4607aa59/710024ddb86e4cc79b2f2a73449bbb88.jpg, createdBy=041e5339211, createdName=胸外科小大夫, createdTime=Tue May 23 20:02:59 CST 2023, time=2023-05-23, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2130113, encodeId=f694213011372, content=五月三日投稿五月四日under review 一个审稿人已经接受了审稿不管中不中这本杂志在我心里都是神刊了处理效率太高了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d7528594085, createdName=ms6000001537745536, createdTime=Thu May 04 21:09:17 CST 2023, time=2023-05-04, status=1, ipAttribution=四川省)]

2023-04-19 王子安那来自天津

审稿速度:1.0 | 投稿命中率:50.0
偏重的研究方向：临床
经验分享：6号投稿，8号接收，19号在线发表，感谢编辑和审稿人，非常高效！

36 9

展开9条回复

[GetPortalCommentsPageByObjectIdResponse(id=2189539, encodeId=b53f218953953, content=偏重的研究方向：肿瘤;生信 经验分享：感觉非常非常不靠谱，一开始发邮件接受了，然后过了一会儿又发邮件说是发错了，给拒绝了。我是第一次这么遇到，太不靠谱了啊这期刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1868855082, createdName=ms8000002119425457, createdTime=Mon Feb 26 22:58:38 CST 2024, time=2024-02-26, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=2127011, encodeId=7336212e011e9, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：临床 经验分享：6号投稿，8号接收，19号在线发表，感谢编辑和审稿人，非常高效！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f2675544063, createdName=王子安那, createdTime=Wed Apr 19 12:29:46 CST 2023, time=2023-04-19, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2102655, encodeId=ad512102655db, content=偏重的研究方向：肿瘤 经验分享：11.16 submissions 11.17 Technical check in progress/ ready to be assigned to an editor 11.18 assigned editor 11.24 10 reviewers invited/ two reviewers accepted 11.25 1 Reviewer report received, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=84dc8360635, createdName=ms7000002055690251, createdTime=Fri Nov 25 22:06:27 CST 2022, time=2022-11-25, status=1, ipAttribution=东京都), GetPortalCommentsPageByObjectIdResponse(id=2151334, encodeId=ea63215133452, content=审稿速度:1.0 | 投稿命中率:95.0 经验分享：2023.07.13投稿 2023.07.23返修 2023.07.26上传返修稿 2023.08.04接受，整个过程20天，效率极高的杂志。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e5256534162, createdName=ms1000001224469901, createdTime=Fri Aug 04 22:14:11 CST 2023, time=2023-08-04, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2184341, encodeId=1c702184341fc, content=偏重的研究方向：肿瘤;基础 经验分享：有没有投过的前辈清楚，6个审稿人邀请16天了，也没人接受审稿，后续会怎么样，做的方向很大众化，感觉审稿人应该也不难找啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=15, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=52758133520, createdName=ms8000001112033195, createdTime=Sat Jan 27 22:14:24 CST 2024, time=2024-01-27, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2145621, encodeId=89262145621c2, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：肿瘤;生信 经验分享：肿瘤生信加了qPCR Submission status Date 29 Jun 2023 Submission accepted 29 Jun 2023 Submission under peer review 24 May 2023 Submission passed technical check 24 May 2023 Submission is under technical check 23 May 2023 Submission received 23 May 2023 一个月直接接收没有返修...现在还是懵的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=18, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=acc08219218, createdName=ms6000000533964556, createdTime=Fri Jun 30 09:58:44 CST 2023, time=2023-06-30, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2151188, encodeId=6f3b215118896, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤 经验分享：Part 1 审稿流程 Part 2 论坛常见问题审稿流程如下： 2023-06-20 投稿 2023-06-20 技术检查通过，安排审稿人 2023-06-23 第一个审稿人接受审稿 2023-06-25 第二个审稿人接受审稿 2023-07-01 第一个审稿意见已回 2023-07-07 第二个审稿意见已回 2023-07-09 编辑汇总意见建议小修 2023-07-13 提交返修 2023-07-25 接受后续包括编辑初步校对，选择OA还是非OA，最后校对都是在2、3天内完成，效率很高常见问题 1、文章参考格式：Endnote APA 6th（稍微参考一下既往杂志文章都不会问出这问题） 2、投稿状态的顺序：Under review（稿件进入投稿流程）→Reviewer Accepted（有审稿人开始审你的稿件了）→Reviews report received（编辑收到了审稿人的意见）→Reviewer reports received/ Ready for editor' s decision（所有的审稿人意见都回来之后，才会开始进入编辑审查阶段，等待编辑汇总意见之后会发给你对文章的处理决定） 3、回顾性研究，case report，基础，生信，meta都收录，被秒拒的大多是优先级不够或者没有任何亮点，纯生信不加试验没有亮点凭啥接收呢？杂志审稿人态度还是很端正的，结合审稿意见来看对文章的大方向和细节都是有要求的，没有给人不专业和水分较深的感觉 4、不建议文章在未发布前共享到Research Square平台上，在投稿时把那个选项X掉比较好 5、杂志可以共同通讯，在文章中标注清楚即可 6、在进入审稿流程后，所有的文章动态更新都只有通讯作者邮箱才能收到，第一作者如需及时了解动态建议勤登网站查看进程 7、OA和非OA在后续文章处理上没有任何区别，OA文章在增加引用量上有其固有优势，掏钱发文章这种事见仁见智，btw这个杂志APC偏贵, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=220, replyNumber=34, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f0b56493364, createdName=ms1000001633014790, createdTime=Thu Aug 03 23:00:50 CST 2023, time=2023-08-03, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2172859, encodeId=f3e821e285931, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：乳腺癌;蛋白家族 经验分享：Publishing and rights Submission status Date Publishing and rights complete 02 Sep 2023 Submission is in publishing and rights 28 Aug 2023 Peer review Submission status Date Submission accepted 17 Aug 2023 Submission under peer review 15 Aug 2023 Submission passed technical check 15 Aug 2023 Revision received 15 Aug 2023 Submission under peer review 13 Jul 2023 Technical check Submission status Date Submission passed technical check 13 Jul 2023 Amendment received 12 Jul 2023 Submission is under technical check 11 Jul 2023 Submission received Submission status Date Submission received 11 Jul 2023 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29e18780767, createdName=ms8000001760882210, createdTime=Mon Dec 04 13:56:12 CST 2023, time=2023-12-04, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2138638, encodeId=c55d213863802, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：外科;综述 经验分享：4.13投稿，5.23接收。一个月多一点直接接收。特别有效率。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221102/369591c85731477baa49cc9e4607aa59/710024ddb86e4cc79b2f2a73449bbb88.jpg, createdBy=041e5339211, createdName=胸外科小大夫, createdTime=Tue May 23 20:02:59 CST 2023, time=2023-05-23, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2130113, encodeId=f694213011372, content=五月三日投稿五月四日under review 一个审稿人已经接受了审稿不管中不中这本杂志在我心里都是神刊了处理效率太高了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d7528594085, createdName=ms6000001537745536, createdTime=Thu May 04 21:09:17 CST 2023, time=2023-05-04, status=1, ipAttribution=四川省)]

2022-11-25 ms7000002055690251 来自东京都

偏重的研究方向：肿瘤
经验分享：11.16 submissions
11.17 Technical check in progress/ ready to be assigned to an editor
11.18 assigned editor
11.24 10 reviewers invited/ two reviewers accepted
11.25 1 Reviewer report received

54 10

展开10条回复

[GetPortalCommentsPageByObjectIdResponse(id=2189539, encodeId=b53f218953953, content=偏重的研究方向：肿瘤;生信 经验分享：感觉非常非常不靠谱，一开始发邮件接受了，然后过了一会儿又发邮件说是发错了，给拒绝了。我是第一次这么遇到，太不靠谱了啊这期刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1868855082, createdName=ms8000002119425457, createdTime=Mon Feb 26 22:58:38 CST 2024, time=2024-02-26, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=2127011, encodeId=7336212e011e9, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：临床 经验分享：6号投稿，8号接收，19号在线发表，感谢编辑和审稿人，非常高效！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f2675544063, createdName=王子安那, createdTime=Wed Apr 19 12:29:46 CST 2023, time=2023-04-19, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2102655, encodeId=ad512102655db, content=偏重的研究方向：肿瘤 经验分享：11.16 submissions 11.17 Technical check in progress/ ready to be assigned to an editor 11.18 assigned editor 11.24 10 reviewers invited/ two reviewers accepted 11.25 1 Reviewer report received, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=84dc8360635, createdName=ms7000002055690251, createdTime=Fri Nov 25 22:06:27 CST 2022, time=2022-11-25, status=1, ipAttribution=东京都), GetPortalCommentsPageByObjectIdResponse(id=2151334, encodeId=ea63215133452, content=审稿速度:1.0 | 投稿命中率:95.0 经验分享：2023.07.13投稿 2023.07.23返修 2023.07.26上传返修稿 2023.08.04接受，整个过程20天，效率极高的杂志。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e5256534162, createdName=ms1000001224469901, createdTime=Fri Aug 04 22:14:11 CST 2023, time=2023-08-04, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2184341, encodeId=1c702184341fc, content=偏重的研究方向：肿瘤;基础 经验分享：有没有投过的前辈清楚，6个审稿人邀请16天了，也没人接受审稿，后续会怎么样，做的方向很大众化，感觉审稿人应该也不难找啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=15, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=52758133520, createdName=ms8000001112033195, createdTime=Sat Jan 27 22:14:24 CST 2024, time=2024-01-27, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2145621, encodeId=89262145621c2, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：肿瘤;生信 经验分享：肿瘤生信加了qPCR Submission status Date 29 Jun 2023 Submission accepted 29 Jun 2023 Submission under peer review 24 May 2023 Submission passed technical check 24 May 2023 Submission is under technical check 23 May 2023 Submission received 23 May 2023 一个月直接接收没有返修...现在还是懵的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=18, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=acc08219218, createdName=ms6000000533964556, createdTime=Fri Jun 30 09:58:44 CST 2023, time=2023-06-30, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2151188, encodeId=6f3b215118896, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤 经验分享：Part 1 审稿流程 Part 2 论坛常见问题审稿流程如下： 2023-06-20 投稿 2023-06-20 技术检查通过，安排审稿人 2023-06-23 第一个审稿人接受审稿 2023-06-25 第二个审稿人接受审稿 2023-07-01 第一个审稿意见已回 2023-07-07 第二个审稿意见已回 2023-07-09 编辑汇总意见建议小修 2023-07-13 提交返修 2023-07-25 接受后续包括编辑初步校对，选择OA还是非OA，最后校对都是在2、3天内完成，效率很高常见问题 1、文章参考格式：Endnote APA 6th（稍微参考一下既往杂志文章都不会问出这问题） 2、投稿状态的顺序：Under review（稿件进入投稿流程）→Reviewer Accepted（有审稿人开始审你的稿件了）→Reviews report received（编辑收到了审稿人的意见）→Reviewer reports received/ Ready for editor' s decision（所有的审稿人意见都回来之后，才会开始进入编辑审查阶段，等待编辑汇总意见之后会发给你对文章的处理决定） 3、回顾性研究，case report，基础，生信，meta都收录，被秒拒的大多是优先级不够或者没有任何亮点，纯生信不加试验没有亮点凭啥接收呢？杂志审稿人态度还是很端正的，结合审稿意见来看对文章的大方向和细节都是有要求的，没有给人不专业和水分较深的感觉 4、不建议文章在未发布前共享到Research Square平台上，在投稿时把那个选项X掉比较好 5、杂志可以共同通讯，在文章中标注清楚即可 6、在进入审稿流程后，所有的文章动态更新都只有通讯作者邮箱才能收到，第一作者如需及时了解动态建议勤登网站查看进程 7、OA和非OA在后续文章处理上没有任何区别，OA文章在增加引用量上有其固有优势，掏钱发文章这种事见仁见智，btw这个杂志APC偏贵, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=220, replyNumber=34, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f0b56493364, createdName=ms1000001633014790, createdTime=Thu Aug 03 23:00:50 CST 2023, time=2023-08-03, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2172859, encodeId=f3e821e285931, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：乳腺癌;蛋白家族 经验分享：Publishing and rights Submission status Date Publishing and rights complete 02 Sep 2023 Submission is in publishing and rights 28 Aug 2023 Peer review Submission status Date Submission accepted 17 Aug 2023 Submission under peer review 15 Aug 2023 Submission passed technical check 15 Aug 2023 Revision received 15 Aug 2023 Submission under peer review 13 Jul 2023 Technical check Submission status Date Submission passed technical check 13 Jul 2023 Amendment received 12 Jul 2023 Submission is under technical check 11 Jul 2023 Submission received Submission status Date Submission received 11 Jul 2023 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29e18780767, createdName=ms8000001760882210, createdTime=Mon Dec 04 13:56:12 CST 2023, time=2023-12-04, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2138638, encodeId=c55d213863802, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：外科;综述 经验分享：4.13投稿，5.23接收。一个月多一点直接接收。特别有效率。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221102/369591c85731477baa49cc9e4607aa59/710024ddb86e4cc79b2f2a73449bbb88.jpg, createdBy=041e5339211, createdName=胸外科小大夫, createdTime=Tue May 23 20:02:59 CST 2023, time=2023-05-23, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2130113, encodeId=f694213011372, content=五月三日投稿五月四日under review 一个审稿人已经接受了审稿不管中不中这本杂志在我心里都是神刊了处理效率太高了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d7528594085, createdName=ms6000001537745536, createdTime=Thu May 04 21:09:17 CST 2023, time=2023-05-04, status=1, ipAttribution=四川省)]

2023-08-04 ms1000001224469901 来自河南省

审稿速度:1.0 | 投稿命中率:95.0
经验分享：2023.07.13投稿
2023.07.23返修
2023.07.26上传返修稿
2023.08.04接受，整个过程20天，效率极高的杂志。

37 12

展开12条回复

[GetPortalCommentsPageByObjectIdResponse(id=2189539, encodeId=b53f218953953, content=偏重的研究方向：肿瘤;生信 经验分享：感觉非常非常不靠谱，一开始发邮件接受了，然后过了一会儿又发邮件说是发错了，给拒绝了。我是第一次这么遇到，太不靠谱了啊这期刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1868855082, createdName=ms8000002119425457, createdTime=Mon Feb 26 22:58:38 CST 2024, time=2024-02-26, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=2127011, encodeId=7336212e011e9, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：临床 经验分享：6号投稿，8号接收，19号在线发表，感谢编辑和审稿人，非常高效！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f2675544063, createdName=王子安那, createdTime=Wed Apr 19 12:29:46 CST 2023, time=2023-04-19, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2102655, encodeId=ad512102655db, content=偏重的研究方向：肿瘤 经验分享：11.16 submissions 11.17 Technical check in progress/ ready to be assigned to an editor 11.18 assigned editor 11.24 10 reviewers invited/ two reviewers accepted 11.25 1 Reviewer report received, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=84dc8360635, createdName=ms7000002055690251, createdTime=Fri Nov 25 22:06:27 CST 2022, time=2022-11-25, status=1, ipAttribution=东京都), GetPortalCommentsPageByObjectIdResponse(id=2151334, encodeId=ea63215133452, content=审稿速度:1.0 | 投稿命中率:95.0 经验分享：2023.07.13投稿 2023.07.23返修 2023.07.26上传返修稿 2023.08.04接受，整个过程20天，效率极高的杂志。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e5256534162, createdName=ms1000001224469901, createdTime=Fri Aug 04 22:14:11 CST 2023, time=2023-08-04, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2184341, encodeId=1c702184341fc, content=偏重的研究方向：肿瘤;基础 经验分享：有没有投过的前辈清楚，6个审稿人邀请16天了，也没人接受审稿，后续会怎么样，做的方向很大众化，感觉审稿人应该也不难找啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=15, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=52758133520, createdName=ms8000001112033195, createdTime=Sat Jan 27 22:14:24 CST 2024, time=2024-01-27, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2145621, encodeId=89262145621c2, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：肿瘤;生信 经验分享：肿瘤生信加了qPCR Submission status Date 29 Jun 2023 Submission accepted 29 Jun 2023 Submission under peer review 24 May 2023 Submission passed technical check 24 May 2023 Submission is under technical check 23 May 2023 Submission received 23 May 2023 一个月直接接收没有返修...现在还是懵的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=18, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=acc08219218, createdName=ms6000000533964556, createdTime=Fri Jun 30 09:58:44 CST 2023, time=2023-06-30, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2151188, encodeId=6f3b215118896, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤 经验分享：Part 1 审稿流程 Part 2 论坛常见问题审稿流程如下： 2023-06-20 投稿 2023-06-20 技术检查通过，安排审稿人 2023-06-23 第一个审稿人接受审稿 2023-06-25 第二个审稿人接受审稿 2023-07-01 第一个审稿意见已回 2023-07-07 第二个审稿意见已回 2023-07-09 编辑汇总意见建议小修 2023-07-13 提交返修 2023-07-25 接受后续包括编辑初步校对，选择OA还是非OA，最后校对都是在2、3天内完成，效率很高常见问题 1、文章参考格式：Endnote APA 6th（稍微参考一下既往杂志文章都不会问出这问题） 2、投稿状态的顺序：Under review（稿件进入投稿流程）→Reviewer Accepted（有审稿人开始审你的稿件了）→Reviews report received（编辑收到了审稿人的意见）→Reviewer reports received/ Ready for editor' s decision（所有的审稿人意见都回来之后，才会开始进入编辑审查阶段，等待编辑汇总意见之后会发给你对文章的处理决定） 3、回顾性研究，case report，基础，生信，meta都收录，被秒拒的大多是优先级不够或者没有任何亮点，纯生信不加试验没有亮点凭啥接收呢？杂志审稿人态度还是很端正的，结合审稿意见来看对文章的大方向和细节都是有要求的，没有给人不专业和水分较深的感觉 4、不建议文章在未发布前共享到Research Square平台上，在投稿时把那个选项X掉比较好 5、杂志可以共同通讯，在文章中标注清楚即可 6、在进入审稿流程后，所有的文章动态更新都只有通讯作者邮箱才能收到，第一作者如需及时了解动态建议勤登网站查看进程 7、OA和非OA在后续文章处理上没有任何区别，OA文章在增加引用量上有其固有优势，掏钱发文章这种事见仁见智，btw这个杂志APC偏贵, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=220, replyNumber=34, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f0b56493364, createdName=ms1000001633014790, createdTime=Thu Aug 03 23:00:50 CST 2023, time=2023-08-03, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2172859, encodeId=f3e821e285931, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：乳腺癌;蛋白家族 经验分享：Publishing and rights Submission status Date Publishing and rights complete 02 Sep 2023 Submission is in publishing and rights 28 Aug 2023 Peer review Submission status Date Submission accepted 17 Aug 2023 Submission under peer review 15 Aug 2023 Submission passed technical check 15 Aug 2023 Revision received 15 Aug 2023 Submission under peer review 13 Jul 2023 Technical check Submission status Date Submission passed technical check 13 Jul 2023 Amendment received 12 Jul 2023 Submission is under technical check 11 Jul 2023 Submission received Submission status Date Submission received 11 Jul 2023 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29e18780767, createdName=ms8000001760882210, createdTime=Mon Dec 04 13:56:12 CST 2023, time=2023-12-04, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2138638, encodeId=c55d213863802, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：外科;综述 经验分享：4.13投稿，5.23接收。一个月多一点直接接收。特别有效率。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221102/369591c85731477baa49cc9e4607aa59/710024ddb86e4cc79b2f2a73449bbb88.jpg, createdBy=041e5339211, createdName=胸外科小大夫, createdTime=Tue May 23 20:02:59 CST 2023, time=2023-05-23, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2130113, encodeId=f694213011372, content=五月三日投稿五月四日under review 一个审稿人已经接受了审稿不管中不中这本杂志在我心里都是神刊了处理效率太高了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d7528594085, createdName=ms6000001537745536, createdTime=Thu May 04 21:09:17 CST 2023, time=2023-05-04, status=1, ipAttribution=四川省)]

2024-01-27 ms8000001112033195 来自安徽省

偏重的研究方向：肿瘤;基础
经验分享：有没有投过的前辈清楚，6个审稿人邀请16天了，也没人接受审稿，后续会怎么样，做的方向很大众化，感觉审稿人应该也不难找啊

15 5

展开5条回复

[GetPortalCommentsPageByObjectIdResponse(id=2189539, encodeId=b53f218953953, content=偏重的研究方向：肿瘤;生信 经验分享：感觉非常非常不靠谱，一开始发邮件接受了，然后过了一会儿又发邮件说是发错了，给拒绝了。我是第一次这么遇到，太不靠谱了啊这期刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1868855082, createdName=ms8000002119425457, createdTime=Mon Feb 26 22:58:38 CST 2024, time=2024-02-26, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=2127011, encodeId=7336212e011e9, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：临床 经验分享：6号投稿，8号接收，19号在线发表，感谢编辑和审稿人，非常高效！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f2675544063, createdName=王子安那, createdTime=Wed Apr 19 12:29:46 CST 2023, time=2023-04-19, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2102655, encodeId=ad512102655db, content=偏重的研究方向：肿瘤 经验分享：11.16 submissions 11.17 Technical check in progress/ ready to be assigned to an editor 11.18 assigned editor 11.24 10 reviewers invited/ two reviewers accepted 11.25 1 Reviewer report received, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=84dc8360635, createdName=ms7000002055690251, createdTime=Fri Nov 25 22:06:27 CST 2022, time=2022-11-25, status=1, ipAttribution=东京都), GetPortalCommentsPageByObjectIdResponse(id=2151334, encodeId=ea63215133452, content=审稿速度:1.0 | 投稿命中率:95.0 经验分享：2023.07.13投稿 2023.07.23返修 2023.07.26上传返修稿 2023.08.04接受，整个过程20天，效率极高的杂志。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e5256534162, createdName=ms1000001224469901, createdTime=Fri Aug 04 22:14:11 CST 2023, time=2023-08-04, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2184341, encodeId=1c702184341fc, content=偏重的研究方向：肿瘤;基础 经验分享：有没有投过的前辈清楚，6个审稿人邀请16天了，也没人接受审稿，后续会怎么样，做的方向很大众化，感觉审稿人应该也不难找啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=15, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=52758133520, createdName=ms8000001112033195, createdTime=Sat Jan 27 22:14:24 CST 2024, time=2024-01-27, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2145621, encodeId=89262145621c2, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：肿瘤;生信 经验分享：肿瘤生信加了qPCR Submission status Date 29 Jun 2023 Submission accepted 29 Jun 2023 Submission under peer review 24 May 2023 Submission passed technical check 24 May 2023 Submission is under technical check 23 May 2023 Submission received 23 May 2023 一个月直接接收没有返修...现在还是懵的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=18, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=acc08219218, createdName=ms6000000533964556, createdTime=Fri Jun 30 09:58:44 CST 2023, time=2023-06-30, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2151188, encodeId=6f3b215118896, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤 经验分享：Part 1 审稿流程 Part 2 论坛常见问题审稿流程如下： 2023-06-20 投稿 2023-06-20 技术检查通过，安排审稿人 2023-06-23 第一个审稿人接受审稿 2023-06-25 第二个审稿人接受审稿 2023-07-01 第一个审稿意见已回 2023-07-07 第二个审稿意见已回 2023-07-09 编辑汇总意见建议小修 2023-07-13 提交返修 2023-07-25 接受后续包括编辑初步校对，选择OA还是非OA，最后校对都是在2、3天内完成，效率很高常见问题 1、文章参考格式：Endnote APA 6th（稍微参考一下既往杂志文章都不会问出这问题） 2、投稿状态的顺序：Under review（稿件进入投稿流程）→Reviewer Accepted（有审稿人开始审你的稿件了）→Reviews report received（编辑收到了审稿人的意见）→Reviewer reports received/ Ready for editor' s decision（所有的审稿人意见都回来之后，才会开始进入编辑审查阶段，等待编辑汇总意见之后会发给你对文章的处理决定） 3、回顾性研究，case report，基础，生信，meta都收录，被秒拒的大多是优先级不够或者没有任何亮点，纯生信不加试验没有亮点凭啥接收呢？杂志审稿人态度还是很端正的，结合审稿意见来看对文章的大方向和细节都是有要求的，没有给人不专业和水分较深的感觉 4、不建议文章在未发布前共享到Research Square平台上，在投稿时把那个选项X掉比较好 5、杂志可以共同通讯，在文章中标注清楚即可 6、在进入审稿流程后，所有的文章动态更新都只有通讯作者邮箱才能收到，第一作者如需及时了解动态建议勤登网站查看进程 7、OA和非OA在后续文章处理上没有任何区别，OA文章在增加引用量上有其固有优势，掏钱发文章这种事见仁见智，btw这个杂志APC偏贵, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=220, replyNumber=34, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f0b56493364, createdName=ms1000001633014790, createdTime=Thu Aug 03 23:00:50 CST 2023, time=2023-08-03, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2172859, encodeId=f3e821e285931, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：乳腺癌;蛋白家族 经验分享：Publishing and rights Submission status Date Publishing and rights complete 02 Sep 2023 Submission is in publishing and rights 28 Aug 2023 Peer review Submission status Date Submission accepted 17 Aug 2023 Submission under peer review 15 Aug 2023 Submission passed technical check 15 Aug 2023 Revision received 15 Aug 2023 Submission under peer review 13 Jul 2023 Technical check Submission status Date Submission passed technical check 13 Jul 2023 Amendment received 12 Jul 2023 Submission is under technical check 11 Jul 2023 Submission received Submission status Date Submission received 11 Jul 2023 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29e18780767, createdName=ms8000001760882210, createdTime=Mon Dec 04 13:56:12 CST 2023, time=2023-12-04, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2138638, encodeId=c55d213863802, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：外科;综述 经验分享：4.13投稿，5.23接收。一个月多一点直接接收。特别有效率。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221102/369591c85731477baa49cc9e4607aa59/710024ddb86e4cc79b2f2a73449bbb88.jpg, createdBy=041e5339211, createdName=胸外科小大夫, createdTime=Tue May 23 20:02:59 CST 2023, time=2023-05-23, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2130113, encodeId=f694213011372, content=五月三日投稿五月四日under review 一个审稿人已经接受了审稿不管中不中这本杂志在我心里都是神刊了处理效率太高了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d7528594085, createdName=ms6000001537745536, createdTime=Thu May 04 21:09:17 CST 2023, time=2023-05-04, status=1, ipAttribution=四川省)]

2023-06-30 ms6000000533964556 来自山东省

审稿速度:1.0 | 投稿命中率:95.0
偏重的研究方向：肿瘤;生信
经验分享：肿瘤生信加了qPCR
Submission status Date
29 Jun 2023

Submission accepted
29 Jun 2023

Submission under peer review
24 May 2023

Submission passed technical check
24 May 2023

Submission is under technical check
23 May 2023

Submission received
23 May 2023

一个月直接接收没有返修...现在还是懵的

47 18

展开18条回复

[GetPortalCommentsPageByObjectIdResponse(id=2189539, encodeId=b53f218953953, content=偏重的研究方向：肿瘤;生信 经验分享：感觉非常非常不靠谱，一开始发邮件接受了，然后过了一会儿又发邮件说是发错了，给拒绝了。我是第一次这么遇到，太不靠谱了啊这期刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1868855082, createdName=ms8000002119425457, createdTime=Mon Feb 26 22:58:38 CST 2024, time=2024-02-26, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=2127011, encodeId=7336212e011e9, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：临床 经验分享：6号投稿，8号接收，19号在线发表，感谢编辑和审稿人，非常高效！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f2675544063, createdName=王子安那, createdTime=Wed Apr 19 12:29:46 CST 2023, time=2023-04-19, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2102655, encodeId=ad512102655db, content=偏重的研究方向：肿瘤 经验分享：11.16 submissions 11.17 Technical check in progress/ ready to be assigned to an editor 11.18 assigned editor 11.24 10 reviewers invited/ two reviewers accepted 11.25 1 Reviewer report received, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=84dc8360635, createdName=ms7000002055690251, createdTime=Fri Nov 25 22:06:27 CST 2022, time=2022-11-25, status=1, ipAttribution=东京都), GetPortalCommentsPageByObjectIdResponse(id=2151334, encodeId=ea63215133452, content=审稿速度:1.0 | 投稿命中率:95.0 经验分享：2023.07.13投稿 2023.07.23返修 2023.07.26上传返修稿 2023.08.04接受，整个过程20天，效率极高的杂志。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e5256534162, createdName=ms1000001224469901, createdTime=Fri Aug 04 22:14:11 CST 2023, time=2023-08-04, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2184341, encodeId=1c702184341fc, content=偏重的研究方向：肿瘤;基础 经验分享：有没有投过的前辈清楚，6个审稿人邀请16天了，也没人接受审稿，后续会怎么样，做的方向很大众化，感觉审稿人应该也不难找啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=15, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=52758133520, createdName=ms8000001112033195, createdTime=Sat Jan 27 22:14:24 CST 2024, time=2024-01-27, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2145621, encodeId=89262145621c2, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：肿瘤;生信 经验分享：肿瘤生信加了qPCR Submission status Date 29 Jun 2023 Submission accepted 29 Jun 2023 Submission under peer review 24 May 2023 Submission passed technical check 24 May 2023 Submission is under technical check 23 May 2023 Submission received 23 May 2023 一个月直接接收没有返修...现在还是懵的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=18, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=acc08219218, createdName=ms6000000533964556, createdTime=Fri Jun 30 09:58:44 CST 2023, time=2023-06-30, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2151188, encodeId=6f3b215118896, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤 经验分享：Part 1 审稿流程 Part 2 论坛常见问题审稿流程如下： 2023-06-20 投稿 2023-06-20 技术检查通过，安排审稿人 2023-06-23 第一个审稿人接受审稿 2023-06-25 第二个审稿人接受审稿 2023-07-01 第一个审稿意见已回 2023-07-07 第二个审稿意见已回 2023-07-09 编辑汇总意见建议小修 2023-07-13 提交返修 2023-07-25 接受后续包括编辑初步校对，选择OA还是非OA，最后校对都是在2、3天内完成，效率很高常见问题 1、文章参考格式：Endnote APA 6th（稍微参考一下既往杂志文章都不会问出这问题） 2、投稿状态的顺序：Under review（稿件进入投稿流程）→Reviewer Accepted（有审稿人开始审你的稿件了）→Reviews report received（编辑收到了审稿人的意见）→Reviewer reports received/ Ready for editor' s decision（所有的审稿人意见都回来之后，才会开始进入编辑审查阶段，等待编辑汇总意见之后会发给你对文章的处理决定） 3、回顾性研究，case report，基础，生信，meta都收录，被秒拒的大多是优先级不够或者没有任何亮点，纯生信不加试验没有亮点凭啥接收呢？杂志审稿人态度还是很端正的，结合审稿意见来看对文章的大方向和细节都是有要求的，没有给人不专业和水分较深的感觉 4、不建议文章在未发布前共享到Research Square平台上，在投稿时把那个选项X掉比较好 5、杂志可以共同通讯，在文章中标注清楚即可 6、在进入审稿流程后，所有的文章动态更新都只有通讯作者邮箱才能收到，第一作者如需及时了解动态建议勤登网站查看进程 7、OA和非OA在后续文章处理上没有任何区别，OA文章在增加引用量上有其固有优势，掏钱发文章这种事见仁见智，btw这个杂志APC偏贵, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=220, replyNumber=34, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f0b56493364, createdName=ms1000001633014790, createdTime=Thu Aug 03 23:00:50 CST 2023, time=2023-08-03, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2172859, encodeId=f3e821e285931, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：乳腺癌;蛋白家族 经验分享：Publishing and rights Submission status Date Publishing and rights complete 02 Sep 2023 Submission is in publishing and rights 28 Aug 2023 Peer review Submission status Date Submission accepted 17 Aug 2023 Submission under peer review 15 Aug 2023 Submission passed technical check 15 Aug 2023 Revision received 15 Aug 2023 Submission under peer review 13 Jul 2023 Technical check Submission status Date Submission passed technical check 13 Jul 2023 Amendment received 12 Jul 2023 Submission is under technical check 11 Jul 2023 Submission received Submission status Date Submission received 11 Jul 2023 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29e18780767, createdName=ms8000001760882210, createdTime=Mon Dec 04 13:56:12 CST 2023, time=2023-12-04, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2138638, encodeId=c55d213863802, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：外科;综述 经验分享：4.13投稿，5.23接收。一个月多一点直接接收。特别有效率。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221102/369591c85731477baa49cc9e4607aa59/710024ddb86e4cc79b2f2a73449bbb88.jpg, createdBy=041e5339211, createdName=胸外科小大夫, createdTime=Tue May 23 20:02:59 CST 2023, time=2023-05-23, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2130113, encodeId=f694213011372, content=五月三日投稿五月四日under review 一个审稿人已经接受了审稿不管中不中这本杂志在我心里都是神刊了处理效率太高了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d7528594085, createdName=ms6000001537745536, createdTime=Thu May 04 21:09:17 CST 2023, time=2023-05-04, status=1, ipAttribution=四川省)]

2023-08-03 ms1000001633014790 来自陕西省

审稿速度:2.0 | 投稿命中率:75.0
偏重的研究方向：肿瘤
经验分享：Part 1 审稿流程 Part 2 论坛常见问题审稿流程如下： 2023-06-20 投稿 2023-06-20 技术检查通过，安排审稿人 2023-06-23 第一个审稿人接受审稿 2023-06-25 第二个审稿人接受审稿 2023-07-01 第一个审稿意见已回 2023-07-07 第二个审稿意见已回 2023-07-09 编辑汇总意见建议小修 2023-07-13 提交返修 2023-07-25 接受后续包括编辑初步校对，选择OA还是非OA，最后校对都是在2、3天内完成，效率很高常见问题 1、文章参考格式：Endnote APA 6th（稍微参考一下既往杂志文章都不会问出这问题） 2、投稿状态的顺序：Under review（稿件进入投稿流程）→Reviewer Accepted（有审稿人开始审你的稿件了）→Reviews report received（编辑收到了审稿人的意见）→Reviewer reports received/ Ready for editor' s decision（所有的审稿人意见都回来之后，才会开始进入编辑审查阶段，等待编辑汇总意见之后会发给你对文章的处理决定） 3、回顾性研究，case report，基础，生信，meta都收录，被秒拒的大多是优先级不够或者没有任何亮点，纯生信不加试验没有亮点凭啥接收呢？杂志审稿人态度还是很端正的，结合审稿意见来看对文章的大方向和细节都是有要求的，没有给人不专业和水分较深的感觉 4、不建议文章在未发布前共享到Research Square平台上，在投稿时把那个选项X掉比较好 5、杂志可以共同通讯，在文章中标注清楚即可 6、在进入审稿流程后，所有的文章动态更新都只有通讯作者邮箱才能收到，第一作者如需及时了解动态建议勤登网站查看进程 7、OA和非OA在后续文章处理上没有任何区别，OA文章在增加引用量上有其固有优势，掏钱发文章这种事见仁见智，btw这个杂志APC偏贵

220 34

展开34条回复

[GetPortalCommentsPageByObjectIdResponse(id=2189539, encodeId=b53f218953953, content=偏重的研究方向：肿瘤;生信 经验分享：感觉非常非常不靠谱，一开始发邮件接受了，然后过了一会儿又发邮件说是发错了，给拒绝了。我是第一次这么遇到，太不靠谱了啊这期刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1868855082, createdName=ms8000002119425457, createdTime=Mon Feb 26 22:58:38 CST 2024, time=2024-02-26, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=2127011, encodeId=7336212e011e9, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：临床 经验分享：6号投稿，8号接收，19号在线发表，感谢编辑和审稿人，非常高效！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f2675544063, createdName=王子安那, createdTime=Wed Apr 19 12:29:46 CST 2023, time=2023-04-19, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2102655, encodeId=ad512102655db, content=偏重的研究方向：肿瘤 经验分享：11.16 submissions 11.17 Technical check in progress/ ready to be assigned to an editor 11.18 assigned editor 11.24 10 reviewers invited/ two reviewers accepted 11.25 1 Reviewer report received, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=84dc8360635, createdName=ms7000002055690251, createdTime=Fri Nov 25 22:06:27 CST 2022, time=2022-11-25, status=1, ipAttribution=东京都), GetPortalCommentsPageByObjectIdResponse(id=2151334, encodeId=ea63215133452, content=审稿速度:1.0 | 投稿命中率:95.0 经验分享：2023.07.13投稿 2023.07.23返修 2023.07.26上传返修稿 2023.08.04接受，整个过程20天，效率极高的杂志。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e5256534162, createdName=ms1000001224469901, createdTime=Fri Aug 04 22:14:11 CST 2023, time=2023-08-04, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2184341, encodeId=1c702184341fc, content=偏重的研究方向：肿瘤;基础 经验分享：有没有投过的前辈清楚，6个审稿人邀请16天了，也没人接受审稿，后续会怎么样，做的方向很大众化，感觉审稿人应该也不难找啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=15, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=52758133520, createdName=ms8000001112033195, createdTime=Sat Jan 27 22:14:24 CST 2024, time=2024-01-27, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2145621, encodeId=89262145621c2, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：肿瘤;生信 经验分享：肿瘤生信加了qPCR Submission status Date 29 Jun 2023 Submission accepted 29 Jun 2023 Submission under peer review 24 May 2023 Submission passed technical check 24 May 2023 Submission is under technical check 23 May 2023 Submission received 23 May 2023 一个月直接接收没有返修...现在还是懵的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=18, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=acc08219218, createdName=ms6000000533964556, createdTime=Fri Jun 30 09:58:44 CST 2023, time=2023-06-30, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2151188, encodeId=6f3b215118896, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤 经验分享：Part 1 审稿流程 Part 2 论坛常见问题审稿流程如下： 2023-06-20 投稿 2023-06-20 技术检查通过，安排审稿人 2023-06-23 第一个审稿人接受审稿 2023-06-25 第二个审稿人接受审稿 2023-07-01 第一个审稿意见已回 2023-07-07 第二个审稿意见已回 2023-07-09 编辑汇总意见建议小修 2023-07-13 提交返修 2023-07-25 接受后续包括编辑初步校对，选择OA还是非OA，最后校对都是在2、3天内完成，效率很高常见问题 1、文章参考格式：Endnote APA 6th（稍微参考一下既往杂志文章都不会问出这问题） 2、投稿状态的顺序：Under review（稿件进入投稿流程）→Reviewer Accepted（有审稿人开始审你的稿件了）→Reviews report received（编辑收到了审稿人的意见）→Reviewer reports received/ Ready for editor' s decision（所有的审稿人意见都回来之后，才会开始进入编辑审查阶段，等待编辑汇总意见之后会发给你对文章的处理决定） 3、回顾性研究，case report，基础，生信，meta都收录，被秒拒的大多是优先级不够或者没有任何亮点，纯生信不加试验没有亮点凭啥接收呢？杂志审稿人态度还是很端正的，结合审稿意见来看对文章的大方向和细节都是有要求的，没有给人不专业和水分较深的感觉 4、不建议文章在未发布前共享到Research Square平台上，在投稿时把那个选项X掉比较好 5、杂志可以共同通讯，在文章中标注清楚即可 6、在进入审稿流程后，所有的文章动态更新都只有通讯作者邮箱才能收到，第一作者如需及时了解动态建议勤登网站查看进程 7、OA和非OA在后续文章处理上没有任何区别，OA文章在增加引用量上有其固有优势，掏钱发文章这种事见仁见智，btw这个杂志APC偏贵, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=220, replyNumber=34, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f0b56493364, createdName=ms1000001633014790, createdTime=Thu Aug 03 23:00:50 CST 2023, time=2023-08-03, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2172859, encodeId=f3e821e285931, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：乳腺癌;蛋白家族 经验分享：Publishing and rights Submission status Date Publishing and rights complete 02 Sep 2023 Submission is in publishing and rights 28 Aug 2023 Peer review Submission status Date Submission accepted 17 Aug 2023 Submission under peer review 15 Aug 2023 Submission passed technical check 15 Aug 2023 Revision received 15 Aug 2023 Submission under peer review 13 Jul 2023 Technical check Submission status Date Submission passed technical check 13 Jul 2023 Amendment received 12 Jul 2023 Submission is under technical check 11 Jul 2023 Submission received Submission status Date Submission received 11 Jul 2023 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29e18780767, createdName=ms8000001760882210, createdTime=Mon Dec 04 13:56:12 CST 2023, time=2023-12-04, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2138638, encodeId=c55d213863802, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：外科;综述 经验分享：4.13投稿，5.23接收。一个月多一点直接接收。特别有效率。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221102/369591c85731477baa49cc9e4607aa59/710024ddb86e4cc79b2f2a73449bbb88.jpg, createdBy=041e5339211, createdName=胸外科小大夫, createdTime=Tue May 23 20:02:59 CST 2023, time=2023-05-23, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2130113, encodeId=f694213011372, content=五月三日投稿五月四日under review 一个审稿人已经接受了审稿不管中不中这本杂志在我心里都是神刊了处理效率太高了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d7528594085, createdName=ms6000001537745536, createdTime=Thu May 04 21:09:17 CST 2023, time=2023-05-04, status=1, ipAttribution=四川省)]

2023-12-04 ms8000001760882210 来自北京

审稿速度:1.0 | 投稿命中率:75.0
偏重的研究方向：乳腺癌;蛋白家族
经验分享：Publishing and rights
Submission status Date
Publishing and rights complete
02 Sep 2023
Submission is in publishing and rights
28 Aug 2023
Peer review
Submission status Date
Submission accepted
17 Aug 2023
Submission under peer review
15 Aug 2023
Submission passed technical check
15 Aug 2023
Revision received
15 Aug 2023
Submission under peer review
13 Jul 2023
Technical check
Submission status Date
Submission passed technical check
13 Jul 2023
Amendment received
12 Jul 2023
Submission is under technical check
11 Jul 2023
Submission received
Submission status Date
Submission received
11 Jul 2023

24 8

展开8条回复

[GetPortalCommentsPageByObjectIdResponse(id=2189539, encodeId=b53f218953953, content=偏重的研究方向：肿瘤;生信 经验分享：感觉非常非常不靠谱，一开始发邮件接受了，然后过了一会儿又发邮件说是发错了，给拒绝了。我是第一次这么遇到，太不靠谱了啊这期刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1868855082, createdName=ms8000002119425457, createdTime=Mon Feb 26 22:58:38 CST 2024, time=2024-02-26, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=2127011, encodeId=7336212e011e9, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：临床 经验分享：6号投稿，8号接收，19号在线发表，感谢编辑和审稿人，非常高效！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f2675544063, createdName=王子安那, createdTime=Wed Apr 19 12:29:46 CST 2023, time=2023-04-19, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2102655, encodeId=ad512102655db, content=偏重的研究方向：肿瘤 经验分享：11.16 submissions 11.17 Technical check in progress/ ready to be assigned to an editor 11.18 assigned editor 11.24 10 reviewers invited/ two reviewers accepted 11.25 1 Reviewer report received, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=84dc8360635, createdName=ms7000002055690251, createdTime=Fri Nov 25 22:06:27 CST 2022, time=2022-11-25, status=1, ipAttribution=东京都), GetPortalCommentsPageByObjectIdResponse(id=2151334, encodeId=ea63215133452, content=审稿速度:1.0 | 投稿命中率:95.0 经验分享：2023.07.13投稿 2023.07.23返修 2023.07.26上传返修稿 2023.08.04接受，整个过程20天，效率极高的杂志。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e5256534162, createdName=ms1000001224469901, createdTime=Fri Aug 04 22:14:11 CST 2023, time=2023-08-04, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2184341, encodeId=1c702184341fc, content=偏重的研究方向：肿瘤;基础 经验分享：有没有投过的前辈清楚，6个审稿人邀请16天了，也没人接受审稿，后续会怎么样，做的方向很大众化，感觉审稿人应该也不难找啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=15, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=52758133520, createdName=ms8000001112033195, createdTime=Sat Jan 27 22:14:24 CST 2024, time=2024-01-27, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2145621, encodeId=89262145621c2, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：肿瘤;生信 经验分享：肿瘤生信加了qPCR Submission status Date 29 Jun 2023 Submission accepted 29 Jun 2023 Submission under peer review 24 May 2023 Submission passed technical check 24 May 2023 Submission is under technical check 23 May 2023 Submission received 23 May 2023 一个月直接接收没有返修...现在还是懵的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=18, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=acc08219218, createdName=ms6000000533964556, createdTime=Fri Jun 30 09:58:44 CST 2023, time=2023-06-30, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2151188, encodeId=6f3b215118896, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤 经验分享：Part 1 审稿流程 Part 2 论坛常见问题审稿流程如下： 2023-06-20 投稿 2023-06-20 技术检查通过，安排审稿人 2023-06-23 第一个审稿人接受审稿 2023-06-25 第二个审稿人接受审稿 2023-07-01 第一个审稿意见已回 2023-07-07 第二个审稿意见已回 2023-07-09 编辑汇总意见建议小修 2023-07-13 提交返修 2023-07-25 接受后续包括编辑初步校对，选择OA还是非OA，最后校对都是在2、3天内完成，效率很高常见问题 1、文章参考格式：Endnote APA 6th（稍微参考一下既往杂志文章都不会问出这问题） 2、投稿状态的顺序：Under review（稿件进入投稿流程）→Reviewer Accepted（有审稿人开始审你的稿件了）→Reviews report received（编辑收到了审稿人的意见）→Reviewer reports received/ Ready for editor' s decision（所有的审稿人意见都回来之后，才会开始进入编辑审查阶段，等待编辑汇总意见之后会发给你对文章的处理决定） 3、回顾性研究，case report，基础，生信，meta都收录，被秒拒的大多是优先级不够或者没有任何亮点，纯生信不加试验没有亮点凭啥接收呢？杂志审稿人态度还是很端正的，结合审稿意见来看对文章的大方向和细节都是有要求的，没有给人不专业和水分较深的感觉 4、不建议文章在未发布前共享到Research Square平台上，在投稿时把那个选项X掉比较好 5、杂志可以共同通讯，在文章中标注清楚即可 6、在进入审稿流程后，所有的文章动态更新都只有通讯作者邮箱才能收到，第一作者如需及时了解动态建议勤登网站查看进程 7、OA和非OA在后续文章处理上没有任何区别，OA文章在增加引用量上有其固有优势，掏钱发文章这种事见仁见智，btw这个杂志APC偏贵, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=220, replyNumber=34, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f0b56493364, createdName=ms1000001633014790, createdTime=Thu Aug 03 23:00:50 CST 2023, time=2023-08-03, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2172859, encodeId=f3e821e285931, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：乳腺癌;蛋白家族 经验分享：Publishing and rights Submission status Date Publishing and rights complete 02 Sep 2023 Submission is in publishing and rights 28 Aug 2023 Peer review Submission status Date Submission accepted 17 Aug 2023 Submission under peer review 15 Aug 2023 Submission passed technical check 15 Aug 2023 Revision received 15 Aug 2023 Submission under peer review 13 Jul 2023 Technical check Submission status Date Submission passed technical check 13 Jul 2023 Amendment received 12 Jul 2023 Submission is under technical check 11 Jul 2023 Submission received Submission status Date Submission received 11 Jul 2023 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29e18780767, createdName=ms8000001760882210, createdTime=Mon Dec 04 13:56:12 CST 2023, time=2023-12-04, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2138638, encodeId=c55d213863802, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：外科;综述 经验分享：4.13投稿，5.23接收。一个月多一点直接接收。特别有效率。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221102/369591c85731477baa49cc9e4607aa59/710024ddb86e4cc79b2f2a73449bbb88.jpg, createdBy=041e5339211, createdName=胸外科小大夫, createdTime=Tue May 23 20:02:59 CST 2023, time=2023-05-23, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2130113, encodeId=f694213011372, content=五月三日投稿五月四日under review 一个审稿人已经接受了审稿不管中不中这本杂志在我心里都是神刊了处理效率太高了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d7528594085, createdName=ms6000001537745536, createdTime=Thu May 04 21:09:17 CST 2023, time=2023-05-04, status=1, ipAttribution=四川省)]

2023-05-23 胸外科小大夫来自辽宁省

审稿速度:2.0 | 投稿命中率:75.0
偏重的研究方向：外科;综述
经验分享：4.13投稿，5.23接收。一个月多一点直接接收。特别有效率。

35 8

展开8条回复

[GetPortalCommentsPageByObjectIdResponse(id=2189539, encodeId=b53f218953953, content=偏重的研究方向：肿瘤;生信 经验分享：感觉非常非常不靠谱，一开始发邮件接受了，然后过了一会儿又发邮件说是发错了，给拒绝了。我是第一次这么遇到，太不靠谱了啊这期刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1868855082, createdName=ms8000002119425457, createdTime=Mon Feb 26 22:58:38 CST 2024, time=2024-02-26, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=2127011, encodeId=7336212e011e9, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：临床 经验分享：6号投稿，8号接收，19号在线发表，感谢编辑和审稿人，非常高效！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f2675544063, createdName=王子安那, createdTime=Wed Apr 19 12:29:46 CST 2023, time=2023-04-19, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2102655, encodeId=ad512102655db, content=偏重的研究方向：肿瘤 经验分享：11.16 submissions 11.17 Technical check in progress/ ready to be assigned to an editor 11.18 assigned editor 11.24 10 reviewers invited/ two reviewers accepted 11.25 1 Reviewer report received, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=84dc8360635, createdName=ms7000002055690251, createdTime=Fri Nov 25 22:06:27 CST 2022, time=2022-11-25, status=1, ipAttribution=东京都), GetPortalCommentsPageByObjectIdResponse(id=2151334, encodeId=ea63215133452, content=审稿速度:1.0 | 投稿命中率:95.0 经验分享：2023.07.13投稿 2023.07.23返修 2023.07.26上传返修稿 2023.08.04接受，整个过程20天，效率极高的杂志。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e5256534162, createdName=ms1000001224469901, createdTime=Fri Aug 04 22:14:11 CST 2023, time=2023-08-04, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2184341, encodeId=1c702184341fc, content=偏重的研究方向：肿瘤;基础 经验分享：有没有投过的前辈清楚，6个审稿人邀请16天了，也没人接受审稿，后续会怎么样，做的方向很大众化，感觉审稿人应该也不难找啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=15, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=52758133520, createdName=ms8000001112033195, createdTime=Sat Jan 27 22:14:24 CST 2024, time=2024-01-27, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2145621, encodeId=89262145621c2, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：肿瘤;生信 经验分享：肿瘤生信加了qPCR Submission status Date 29 Jun 2023 Submission accepted 29 Jun 2023 Submission under peer review 24 May 2023 Submission passed technical check 24 May 2023 Submission is under technical check 23 May 2023 Submission received 23 May 2023 一个月直接接收没有返修...现在还是懵的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=18, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=acc08219218, createdName=ms6000000533964556, createdTime=Fri Jun 30 09:58:44 CST 2023, time=2023-06-30, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2151188, encodeId=6f3b215118896, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤 经验分享：Part 1 审稿流程 Part 2 论坛常见问题审稿流程如下： 2023-06-20 投稿 2023-06-20 技术检查通过，安排审稿人 2023-06-23 第一个审稿人接受审稿 2023-06-25 第二个审稿人接受审稿 2023-07-01 第一个审稿意见已回 2023-07-07 第二个审稿意见已回 2023-07-09 编辑汇总意见建议小修 2023-07-13 提交返修 2023-07-25 接受后续包括编辑初步校对，选择OA还是非OA，最后校对都是在2、3天内完成，效率很高常见问题 1、文章参考格式：Endnote APA 6th（稍微参考一下既往杂志文章都不会问出这问题） 2、投稿状态的顺序：Under review（稿件进入投稿流程）→Reviewer Accepted（有审稿人开始审你的稿件了）→Reviews report received（编辑收到了审稿人的意见）→Reviewer reports received/ Ready for editor' s decision（所有的审稿人意见都回来之后，才会开始进入编辑审查阶段，等待编辑汇总意见之后会发给你对文章的处理决定） 3、回顾性研究，case report，基础，生信，meta都收录，被秒拒的大多是优先级不够或者没有任何亮点，纯生信不加试验没有亮点凭啥接收呢？杂志审稿人态度还是很端正的，结合审稿意见来看对文章的大方向和细节都是有要求的，没有给人不专业和水分较深的感觉 4、不建议文章在未发布前共享到Research Square平台上，在投稿时把那个选项X掉比较好 5、杂志可以共同通讯，在文章中标注清楚即可 6、在进入审稿流程后，所有的文章动态更新都只有通讯作者邮箱才能收到，第一作者如需及时了解动态建议勤登网站查看进程 7、OA和非OA在后续文章处理上没有任何区别，OA文章在增加引用量上有其固有优势，掏钱发文章这种事见仁见智，btw这个杂志APC偏贵, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=220, replyNumber=34, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f0b56493364, createdName=ms1000001633014790, createdTime=Thu Aug 03 23:00:50 CST 2023, time=2023-08-03, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2172859, encodeId=f3e821e285931, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：乳腺癌;蛋白家族 经验分享：Publishing and rights Submission status Date Publishing and rights complete 02 Sep 2023 Submission is in publishing and rights 28 Aug 2023 Peer review Submission status Date Submission accepted 17 Aug 2023 Submission under peer review 15 Aug 2023 Submission passed technical check 15 Aug 2023 Revision received 15 Aug 2023 Submission under peer review 13 Jul 2023 Technical check Submission status Date Submission passed technical check 13 Jul 2023 Amendment received 12 Jul 2023 Submission is under technical check 11 Jul 2023 Submission received Submission status Date Submission received 11 Jul 2023 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29e18780767, createdName=ms8000001760882210, createdTime=Mon Dec 04 13:56:12 CST 2023, time=2023-12-04, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2138638, encodeId=c55d213863802, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：外科;综述 经验分享：4.13投稿，5.23接收。一个月多一点直接接收。特别有效率。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221102/369591c85731477baa49cc9e4607aa59/710024ddb86e4cc79b2f2a73449bbb88.jpg, createdBy=041e5339211, createdName=胸外科小大夫, createdTime=Tue May 23 20:02:59 CST 2023, time=2023-05-23, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2130113, encodeId=f694213011372, content=五月三日投稿五月四日under review 一个审稿人已经接受了审稿不管中不中这本杂志在我心里都是神刊了处理效率太高了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d7528594085, createdName=ms6000001537745536, createdTime=Thu May 04 21:09:17 CST 2023, time=2023-05-04, status=1, ipAttribution=四川省)]

2023-05-04 ms6000001537745536 来自四川省

五月三日投稿五月四日under review 一个审稿人已经接受了审稿不管中不中这本杂志在我心里都是神刊了处理效率太高了

48 12

展开12条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务